Literature DB >> 27920179

Development of Vaccines for Chikungunya Fever.

Jesse H Erasmus1,2,3,4, Shannan L Rossi1,2,3,4, Scott C Weaver1,2,3,4.   

Abstract

Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Chikungunya; alphavirus; arthralgia; vaccine

Mesh:

Substances:

Year:  2016        PMID: 27920179      PMCID: PMC5137239          DOI: 10.1093/infdis/jiw271

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  59 in total

1.  Eilat virus host range restriction is present at multiple levels of the virus life cycle.

Authors:  Farooq Nasar; Rodion V Gorchakov; Robert B Tesh; Scott C Weaver
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.

Authors:  Adam D DeZure; Nina M Berkowitz; Barney S Graham; Julie E Ledgerwood
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

3.  A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.

Authors:  Samantha Brandler; Claude Ruffié; Chantal Combredet; Jean-Baptiste Brault; Valérie Najburg; Marie-Christine Prevost; André Habel; Erich Tauber; Philippe Desprès; Frédéric Tangy
Journal:  Vaccine       Date:  2013-06-04       Impact factor: 3.641

4.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

5.  The use of bi-cistronic transfer vectors for the baculovirus expression system.

Authors:  Y Finkelstein; O Faktor; O Elroy-Stein; B Z Levi
Journal:  J Biotechnol       Date:  1999-09-24       Impact factor: 3.307

6.  A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.

Authors:  Karthik Mallilankaraman; Devon J Shedlock; Huihui Bao; Omkar U Kawalekar; Paolo Fagone; Aarthi A Ramanathan; Bernadette Ferraro; Jennifer Stabenow; Paluru Vijayachari; Senthil G Sundaram; Nagarajan Muruganandam; Gopalsamy Sarangan; Padma Srikanth; Amir S Khan; Mark G Lewis; J Joseph Kim; Niranjan Y Sardesai; Karuppiah Muthumani; David B Weiner
Journal:  PLoS Negl Trop Dis       Date:  2011-01-11

7.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

8.  Prime-boost immunization strategies against Chikungunya virus.

Authors:  David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand.

Authors:  Narong Nitatpattana; Kobkan Kanjanopas; Sutee Yoksan; Wichai Satimai; Narong Vongba; Sasiporn Langdatsuwan; Khajornpong Nakgoi; Supot Ratchakum; Nadia Wauquier; Marc Souris; Prasert Auewarakul; Jean-Paul Gonzalez
Journal:  Virol J       Date:  2014-10-21       Impact factor: 4.099

10.  Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children.

Authors:  Maria Rosario Capeding; Mary Noreen Chua; Sri Rezeki Hadinegoro; Ismail I H M Hussain; Revathy Nallusamy; Punnee Pitisuttithum; Kusnandi Rusmil; Usa Thisyakorn; Stephen J Thomas; Ngoc Huu Tran; Dewa Nyoman Wirawan; In-Kyu Yoon; Alain Bouckenooghe; Yanee Hutagalung; Thelma Laot; Tram Anh Wartel
Journal:  PLoS Negl Trop Dis       Date:  2013-07-25
View more
  27 in total

Review 1.  51 years in of Chikungunya clinical vaccine development: A historical perspective.

Authors:  Arturo Reyes-Sandoval
Journal:  Hum Vaccin Immunother       Date:  2019-04-02       Impact factor: 3.452

Review 2.  O'nyong-nyong fever: a neglected mosquito-borne viral disease.

Authors:  Giovanni Rezza; Rubing Chen; Scott C Weaver
Journal:  Pathog Glob Health       Date:  2017-08-22       Impact factor: 2.894

3.  Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

Authors:  Pierre Roques; Karl Ljungberg; Beate M Kümmerer; Leslie Gosse; Nathalie Dereuddre-Bosquet; Nicolas Tchitchek; David Hallengärd; Juan García-Arriaza; Andreas Meinke; Mariano Esteban; Andres Merits; Roger Le Grand; Peter Liljeström
Journal:  JCI Insight       Date:  2017-03-23

Review 4.  Vaccines for epidemic infections and the role of CEPI.

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2017-04-04       Impact factor: 3.452

Review 5.  Disentangling the Frames, the State of Research on the Alphavirus 6K and TF Proteins.

Authors:  Jolene Ramsey; Suchetana Mukhopadhyay
Journal:  Viruses       Date:  2017-08-18       Impact factor: 5.048

6.  High risk for chikungunya virus to initiate an enzootic sylvatic cycle in the tropical Americas.

Authors:  Ricardo Lourenço-de-Oliveira; Anna-Bella Failloux
Journal:  PLoS Negl Trop Dis       Date:  2017-06-29

7.  Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.

Authors:  Preethi Eldi; Tamara H Cooper; Liang Liu; Natalie A Prow; Kerrilyn R Diener; Paul M Howley; Andreas Suhrbier; John D Hayball
Journal:  Mol Ther       Date:  2017-07-15       Impact factor: 11.454

Review 8.  The Regulation of Translation in Alphavirus-Infected Cells.

Authors:  Luis Carrasco; Miguel Angel Sanz; Esther González-Almela
Journal:  Viruses       Date:  2018-02-08       Impact factor: 5.048

Review 9.  The Alphavirus Exit Pathway: What We Know and What We Wish We Knew.

Authors:  Rebecca S Brown; Judy J Wan; Margaret Kielian
Journal:  Viruses       Date:  2018-02-22       Impact factor: 5.048

Review 10.  Adult Immunization - Need of the Hour.

Authors:  Abhishek Jairaj; P Shirisha; Muqthadir Siddiqui Mohammad Abdul; Urooj Fatima; Rahul Vinay Chandra Tiwari; Muhamood Moothedath
Journal:  J Int Soc Prev Community Dent       Date:  2018-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.